TOP TEN perturbations for 38734_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38734_at
Selected probe(set): 204939_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38734_at (204939_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Relative Expression (log2-ratio):-7.1819553Number of Samples:2 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)
Relative Expression (log2-ratio):7.153181Number of Samples:2 / 5
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, dedifferentiated liposarcoma of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Relative Expression (log2-ratio):7.0846157Number of Samples:2 / 5
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Relative Expression (log2-ratio):-6.9631643Number of Samples:3 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Relative Expression (log2-ratio):-6.7455416Number of Samples:7 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, sarcoma, NOS of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). |
basal cell carcinoma study 3 / normal epidermal keratinocytes
Relative Expression (log2-ratio):5.9806204Number of Samples:4 / 2
Experimental | basal cell carcinoma study 3 |
Primary tumor tissue from the eyelid of patients with basal cell carcinoma (BCC). | |
Control | normal epidermal keratinocytes |
Normal human epidermal keratinocytes (NHEK) (Kurabo Ind., Ltd., Osaka, Japan) cultured in HuMedia-KB2 medium at 37°C in humidified air containing 5% CO2. |
prostate cancer study 1 (meta.) / prostate cancer study 1 (prim.)
Relative Expression (log2-ratio):-5.3885355Number of Samples:6 / 7
Experimental | prostate cancer study 1 (meta.) |
Metastatic prostate cancer samples. | |
Control | prostate cancer study 1 (prim.) |
Primary prostate cancer samples. |
endometriosis study 5 (endo. lesion; proliferative MCP) / endometriosis study 5 (eutopic endometrium; proliferative MCP)
Relative Expression (log2-ratio):5.3458786Number of Samples:8 / 8
Experimental | endometriosis study 5 (endo. lesion; proliferative MCP) |
Peritoneal endometriosis lesion samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, and the knowledge of the patient’s last menstrual cycle. | |
Control | endometriosis study 5 (eutopic endometrium; proliferative MCP) |
Eutopic endometrial tissue samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, the knowledge of the patient’s last menstrual cycle, and analysis of specific histological criteria to identify menstrual cycle phases. |
myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):5.316247Number of Samples:3 / 3
Experimental | myotonic dystrophy study 4 (deltoid muscle; DM2) |
Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
Control | normal skeletal muscle tisuue (fetal) |
Commercially purchased normal fetal skeletal muscle tissue samples. |
prostate cancer study 1 (meta.) / benign prostate tissue
Relative Expression (log2-ratio):-5.249134Number of Samples:6 / 6
Experimental | prostate cancer study 1 (meta.) |
Metastatic prostate cancer samples. | |
Control | benign prostate tissue |
Benign prostate samples. |